Skip to Content
MilliporeSigma
All Photos(5)

Documents

HCCBP3MAG-58K

Millipore

MILLIPLEX® Human Circulating Cancer Biomarker Magnetic Bead Panel 3 - Cancer Multiplex Assay

Circulating Cancer Biomarker Bead-Based Multiplex Assays using the Luminex technology enables the simultaneous analysis of multiple oncology biomarkers in various tumor types in human serum, plasma and cell culture samples.

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
12161503
eCl@ss:
32161000
NACRES:
NA.84

Quality Level

species reactivity

human

manufacturer/tradename

Milliplex®

assay range

accuracy: 74-126%
standard curve range: 0.004-3 ng/mL
(Galectin-3)

standard curve range: 0.02-20 ng/mL
(Myeloperoxidase)

standard curve range: 0.03-25 nM
(Sex Hormone Binding Globulin)

standard curve range: 0.03-25 ng/mL
(Ferritin)

standard curve range: 0.07-50 ng/mL
(Catalase, Fibroblast Activation Protein α)

standard curve range: 0.1-75 ng/mL
(Melanoma Inhibitory Activity Protein)

standard curve range: 0.27-200 ng/mL
(Cathepsin D, IGFBP3)

technique(s)

multiplexing: suitable

detection method

fluorometric (Luminex xMAP)

shipped in

wet ice

General description

Circulating cancer biomarkers give insight beyond intracellular oncogenesis and into how the body responds to the presence of a tumor, the dysregulation of homeostasis, and the relationship between a tumor and its environment. Multianalyte panels have become essential tools that enable researchers to measure cancer biomarkers simultaneously, teasing out these relationships and applying them to understand tumor biology.

MILLIPLEX® Human Circulating Biomarker Panel 3 is an 8-plex kit to be used for the simultaneous quantification or any or all of the following analytes in serum, plasma and tissue/cell lysate and culture supernatant samples: Galectin-3, Cathepsin D, Fibroblast activation protein alpha (FAP), Melanoma inhibitory activity protein (MIA), Myeloperoxidase, Sex hormone binding globulin (SHBG), Insulin like growth factor binding protein 3 (IGFBP3), and Ferritin. This kit uses a 96-well format, contains a lyophilized standard cocktail, two internal assay quality controls and can measure up to 38 samples in duplicate.

The Luminex® xMAP® platform uses a magnetic bead immunoassay format for ideal speed and sensitivity to quantitate multiple analytes simultaneously, dramatically improving productivity while conserving valuable sample volume.

Panel Type: Circulating Cancer

Specificity

Cross Reactivty
Cross-reactivity between the antibodies and any of the other analytes in this panel is non-detectable or negligible.

Application

  • Analytes: Cathepsin D, Ferritin, Fibroblast Activation Protein (FAP), Galectin-3, IGFBP3, Melanoma Inhibitory Activty Protein (MIA), Myeloperoxidase (MPO), Sex Hormone Binding Globulin (SHGB)
  • Recommended Sample Type: Human serum, plasma or tissue/cell culture supernatants or lysates e
  • Recommended Sample Dilution: 25 μL of 1:50 diluted plasma or serum, or 25 μL of diluted tissue/cell lysate or culture supernatant per well (dilution factors may vary). Note: If IGFBP3 is included in the assay, then the recommended dilution for the assay is 1:200
  • Assay Run Time: Overnight (16-18 hr) at 2-4°C
  • Research Category: Cancer

Features and Benefits

Design your multiplex kit by choosing available analytes within this panel.

Packaging

Everything you need in a single kit.

Storage and Stability

Recommended storage for kit components is 2 - 8°C.

Analysis Note

SHBG Standard was calibrated against WHO standard 08/266 and 250 ng/mL standard was equivalent to 25 nM of WHO standard

Other Notes

Sensitivity: Refer to kit protocol for sensitivities of individual biomarkers.

Legal Information

Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

pictograms

Skull and crossbonesEnvironment

signalword

Danger

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Irrit. 2 - Skin Sens. 1

wgk_germany

WGK 3


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Juan Pablo Hinestrosa et al.
Communications medicine, 2, 29-29 (2022-05-24)
Detecting cancer at early stages significantly increases patient survival rates. Because lethal solid tumors often produce few symptoms before progressing to advanced, metastatic disease, diagnosis frequently occurs when surgical resection is no longer curative. One promising approach to detect early-stage

Related Content

Detection of cancer biomarkers through multiplex cancer assays can accelerate studies of normal homeostasis and tumorigenic processes. See how MILLIPLEX® multiplex cancer assays are advancing various cancer research areas including lung cancer, breast cancer, and immuno-oncology research.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service